Literature DB >> 19647269

Role of proton magnetic resonance spectroscopy in preoperative evaluation of patients with mesial temporal lobe epilepsy.

Mikhail F Chernov1, Taku Ochiai, Yuko Ono, Yoshihiro Muragaki, Fumitaka Yamane, Takaomi Taira, Takashi Maruyama, Masahiko Tanaka, Hiroshi Iseki, Osami Kubo, Yoshikazu Okada, Tomokatsu Hori, Kintomo Takakura.   

Abstract

A retrospective study was conducted for evaluation of the role of single-voxel proton magnetic resonance spectroscopy (1H-MRS) in preoperative investigation of patients with mesial temporal lobe epilepsy (MTLE). Eighteen cases, including both non-lesional and lesional MTLE, were analyzed. Selective amygdalohippocampectomy was performed in 8 cases, selective amygdalohippocampectomy combined with lesionectomy in 6 cases, lesionectomy in 3 cases, and anterior temporal lobe resection in one case. The length of follow-up varied from 24 to 71 months (median, 35 months). Before surgery, (1)H-MRS disclosed decrease of N-acetylaspartate (NAA) content (P=0.01) and more frequent (P=0.07) presence of lactate (Lac) on the side of the epileptogenic zone. Decrease of NAA content below 0.75 and/or unilateral presence of Lac provided 86% (95% CI: 68%-100%) lateralization accuracy. Metabolic parameters did not differ in subgroups with hippocampal sclerosis and brain tumors. On the long-term follow-up 12 patients (67%) were free of disabling seizures. There was a trend (P=0.05) for worse seizure outcome in cases with significant bilateral metabolic alterations characterized by predominance of choline-containing compounds' peak on 1H-MR spectra on both sides. In conclusion, 1H-MRS-detected reduction of NAA content and unilateral presence of Lac in the mesial temporal lobe structures may serve as additional diagnostic clues for lateralization of the epileptogenic zone in MTLE. Metabolic imaging has limited usefulness for differentiation of the hippocampal sclerosis and low-grade intraaxial brain tumor. Presence of significant bilateral metabolic alterations in the mesial temporal lobe structures is associated with worse postoperative seizure control.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19647269     DOI: 10.1016/j.jns.2009.07.004

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  The Study of Genetic Susceptibility and Mitochondrial Dysfunction in Mesial Temporal Lobe Epilepsy.

Authors:  Haiyan Yang; Fei Yin; Siyi Gan; Zou Pan; Ting Xiao; Miriam Kessi; Zhuangyi Yang; Victor Wei Zhang; Liwen Wu
Journal:  Mol Neurobiol       Date:  2020-07-06       Impact factor: 5.590

Review 2.  Neuroimaging biomarkers of epileptogenesis.

Authors:  Asht Mangal Mishra; Harrison Bai; Alexandra Gribizis; Hal Blumenfeld
Journal:  Neurosci Lett       Date:  2011-02-16       Impact factor: 3.046

3.  Underutilization of advanced presurgical studies and high rates of vagus nerve stimulation for drug-resistant epilepsy: a single-center experience and recommendations.

Authors:  Elena Solli; Nicole A Colwell; Christopher Markosian; Anmol S Johal; Rebecca Houston; M Omar Iqbal; Irene Say; Joseph I Petrsoric; Luke D Tomycz
Journal:  Acta Neurochir (Wien)       Date:  2021-11-13       Impact factor: 2.216

4.  Evaluation of magnetic resonance imaging-negative drug-resistant epilepsy.

Authors:  Aashit K Shah; Sandeep Mittal
Journal:  Ann Indian Acad Neurol       Date:  2014-03       Impact factor: 1.383

Review 5.  Multimodal neuroimaging in presurgical evaluation of drug-resistant epilepsy.

Authors:  Jing Zhang; Weifang Liu; Hui Chen; Hong Xia; Zhen Zhou; Shanshan Mei; Qingzhu Liu; Yunlin Li
Journal:  Neuroimage Clin       Date:  2013-11-01       Impact factor: 4.881

6.  Identifying the affected hemisphere with a multimodal approach in MRI-positive or negative, unilateral or bilateral temporal lobe epilepsy.

Authors:  Jing Zhang; Qingzhu Liu; Shanshan Mei; Xiaoming Zhang; Weifang Liu; Hui Chen; Hong Xia; Zhen Zhou; Xiaofei Wang; Yunlin Li
Journal:  Neuropsychiatr Dis Treat       Date:  2014-01-07       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.